



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

Mail Stop 4720

June 9, 2016

Jonathan Adams  
Chief Executive Officer  
Nanoantibiotics, Inc.  
100 Cummings Center, Suite 247-C  
Beverly, Massachusetts 01915

**Re: NanoAntibiotics, Inc.  
Current Report on Form 8K  
Filed April 15, 2016  
File No. 000-55292**

**Preliminary Information Statement on Schedule 14C  
Filed April 21, 2016  
File No. 000-55292**

Dear Mr. Adams:

We have completed our review of your filings. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Erin K. Jaskot, *for*

Suzanne Hayes  
Assistant Director  
Office of Healthcare and Insurance